InferMed appoints Cancer Research UK's Dr Sally Burtles as Observer to the Board
- Details
- Category: Business
InferMed, a leading provider of advanced software solutions for clinical research and practice, has appointed Dr Sally Burtles, Director of Drug Development at Cancer Research UK, as an Observer to the Board.
InferMed has a long-standing relationship with Cancer Research UK, and was backed by the charity at its formation in 1999. A research relationship continues with Cancer Research UK, which remains InferMed's largest institutional shareholder.
Court Rules That Roche Infringes One of Amgen's Erythropoietin Patents
- Details
- Category: Amgen

Nexavar Significantly Improved Overall Survival in Phase III Asia-Pacific Liver Cancer Trial
- Details
- Category: Clinical Trials
Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that a planned review by an independent data monitoring committee (DMC) found that Nexavar® (sorafenib) tablets significantly improved overall survival, progression free survival and time to progression in an Asia-Pacific regional Phase III trial of patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. Based on the DMC's recommendation, the trial will be stopped to allow all patients to receive treatment with Nexavar. Data from this study will be submitted for presentation at an upcoming scientific meeting.
Pfizer Names Frank A. D'Amelio Chief Financial Officer
- Details
- Category: Pfizer

Liraglutide improves glucose control and lowers body weight in two phase 3 studies
- Details
- Category: Novo Nordisk

GlaxoSmithKline Signs Contract for its Pandemic Flu Vaccine with UK Government
- Details
- Category: GlaxoSmithKline

Ligand Pharmaceuticals Announces Second Quarter Results
- Details
- Category: Financial
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced financial results for the three months ended June 30, 2007 and provided a business update. The Company sold its commercial oncology product line in October 2006 and sold the AVINZA(R) product line in February 2007.
More Pharma News ...
- Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17
- Availability on line of the sanofi-aventis half-year financial report for 2007
- Merck Announces Fourth Quarter 2007 Dividend
- Key business with prescription medicines continues to boost growth at Boehringer Ingelheim
- New Spiriva® Respimat® inhaler completes European approval process for COPD
- Boehringer Ingelheim announces first international head-to-head trial of Aptivus®
- Recommendation of Approval for the Merz Botulinum Neurotoxin Typ A in European Countries